<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFUROXIME AXETIL FOR ORAL SUSPENSION- cefuroxime axetil suspension </strong><br>Ranbaxy Pharmaceuticals Inc<br></p></div>
<h1>CEFUROXIME AXETIL FOR ORAL SUSPENSION,USP<br>Rx Only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-a53fb40d-583b-48f9-9729-0de5a9c05e82"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><a name="inv-1e8196a2-74b6-4b2a-964d-fbdd18727fd1"></a>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil for oral suspension and other antibacterial drugs, cefuroxime axetil for oral suspension should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="inv-c448fdbd-95a9-4ba7-aa14-77879d8a8343"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><a name="inv-2cd049d9-0e73-4c41-aad2-07aaba999f5d"></a>Cefuroxime axetil for oral suspension, USP contains cefuroxime as cefuroxime axetil. Cefuroxime axetil USP is a semisynthetic, broad-spectrum cephalosporin antibiotic for oral administration.</p>
<p><a name="inv-c827de7f-b939-4241-945d-baf3fbba5c0c"></a>Chemically, cefuroxime axetil, the 1-(acetyloxy) ethyl ester of cefuroxime, is (<span class="Italics">RS</span>)-1- hydroxyethyl (6<span class="Italics">R</span>,7<span class="Italics">R</span>)-7-[2-(2-furyl)glyoxylamido]-3-(hydroxymethyl)-8-oxo-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylate, 7<span class="Sup">2</span>-(<span class="Italics">Z</span>)-(<span class="Italics">O</span>-methyl-oxime), 1-acetate 3-carbamate. Its molecular formula is C<span class="Sub">20</span>H<span class="Sub">22</span>N<span class="Sub">4</span>O<span class="Sub">10</span>S, and it has a molecular weight of 510.48.</p>
<p><a name="inv-c6cd491b-cb7a-4a22-8f87-11260b1be786"></a>Cefuroxime axetil is in the crystalline form and has the following structural formula: </p>
<div class="Figure">
<a name="ID0EWKAC"></a><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=135e2dfc-eb47-4d04-a903-a081d36c267e&amp;name=structure.jpg">
</div>
<p><a name="inv-27691b98-2ad0-4cf8-a549-2bd967d7e92b"></a>Cefuroxime axetil for oral suspension USP, when reconstituted with water, provides the equivalent of 125 mg or 250 mg of cefuroxime (as cefuroxime axetil) per 5 mL of suspension. Cefuroxime axetil USP for oral suspension contains the following inactive ingredients: aspartame, hypromellose phthalate, mannitol, methacrylic acid copolymer, monosodium citrate, peppermint flavor, silicon dioxide, sodium benzoate, sodium chloride, sucrose, tutti frutti flavor, xanthan gum.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="inv-3ebba534-3948-427c-a6b3-052f91f34383"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><a name="inv-7bc31ba2-2617-46e3-890f-bd10b12f69a0"></a><span class="Bold">Absorption and Metabolism: </span>After oral administration, cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to cefuroxime. Cefuroxime is subsequently distributed throughout the extracellular fluids. The axetil moiety is metabolized to acetaldehyde and acetic acid.</p>
<p><a name="inv-5637195a-f9d9-4849-9e98-8e36a4e3b987"></a><span class="Bold">Pharmacokinetics: </span>Approximately 50% of serum cefuroxime is bound to protein. Serum pharmacokinetic parameters for cefuroxime axetil for oral suspension are shown in Table 1.</p>
<a name="inv-598eecc8-3e3d-4be3-8758-6c23812a0ab0"></a><table border="1" frame="border">
<caption><span>Table 1. Postprandial Pharmacokinetics of Cefuroxime Administered as Cefuroxime Axetil for Oral Suspension to Pediatric Patients*</span></caption>
<col width="128.00px">
<col width="64.00px">
<col width="116.00px">
<col width="116.00px">
<col width="100.00px">
<col width="92.00px">
<tbody class="Headless">
<tr class="First">
<td align="center">
 Dose<span class="Sup">†</span> 
 (Cefuroxime
 Equivalent) </td>
<td align="center">
 n </td>
<td align="center">
 Peak Plasma
 Concentration
 (mcg/mL) </td>
<td align="center">
 Time of Peak
 Plasma
 Concentration
 (hr) </td>
<td align="center">
 Mean
 Elimination
 Half-Life
 (hr) </td>
<td align="center">
 AUC
 (mcg-hr mL) </td>
</tr>
<tr>
<td>
 10 mg/kg </td>
<td align="center">
 8 </td>
<td align="center">
 3.3 </td>
<td align="center">
 3.6 </td>
<td align="center">
 1.4 </td>
<td align="center">
 12.4 </td>
</tr>
<tr>
<td>
 15 mg/kg </td>
<td align="center">
 12 </td>
<td align="center">
 5.1 </td>
<td align="center">
 2.7 </td>
<td align="center">
 1.9 </td>
<td align="center">
 22.5 </td>
</tr>
<tr class="Last">
<td>
 20 mg/kg </td>
<td align="center">
 8 </td>
<td align="center">
 7 </td>
<td align="center">
 3.1 </td>
<td align="center">
 1.9 </td>
<td align="center">
 32.8 </td>
</tr>
</tbody>
</table>
<p><a name="inv-3a230d6d-2dfd-4739-9de6-321ca6eb645e"></a><span class="Sup">*</span>Mean age = 23 months.</p>
<p><a name="inv-408610d5-755c-4bab-8211-2bd40dfec05f"></a><span class="Sup">†</span>Drug administered with milk or milk products</p>
<p><a name="inv-945d31c3-a42e-44dc-a7a9-45dad7c7a183"></a><span class="Bold">Comparative Pharmacokinetic Properties: </span>A 250 mg/5 mL dose of cefuroxime axetil for oral suspension is bioequivalent to 2 times 125 mg/5 mL dose of cefuroxime axetil for oral suspension when administered with food (see Table 2). <span class="Bold">Cefuroxime axetil for oral suspension was not bioequivalent to cefuroxime axetil tablets when tested in healthy adults. The tablet and powder for oral suspension formulations are NOT substitutable on a milligram-per-milligram basis.</span> The area under the curve for the suspension averaged 91% of that for the tablet, and the peak plasma concentration for the suspension averaged 71% of the peak plasma concentration of the tablets. Therefore, the safety and effectiveness of both the tablet and oral suspension formulations had to be established in separate clinical trials.</p>
<a name="inv-f706fcd0-983f-4ef2-8ef7-b74210ab133d"></a><table border="1" frame="border">
<caption><span>Table 2: Pharmacokinetics of Cefuroxime Administered as 250 mg/5 mL or 2 x 125 mg/5 mL Cefuroxime Axetil for Oral Suspension to Adults* With Food</span></caption>
<col width="180.00px">
<col width="104.00px">
<col width="124.00px">
<col width="96.00px">
<col width="84.00px">
<tbody class="Headless">
<tr class="First">
<td align="center">
 Dose
 (Cefuroxime
 Equivalent) </td>
<td align="center">
 Peak Plasma
 Concentration
 (mcg/mL) </td>
<td align="center">
 Time of Peak
 Plasma
 Concentration (hr) </td>
<td align="center">
 Mean
 Elimination
 Half-Life (hr) </td>
<td align="center">
 AUC
 (mcg-hr mL) </td>
</tr>
<tr>
<td>
 250 mg/5 mL </td>
<td align="center">
 2.23 </td>
<td align="center">
 3 </td>
<td align="center">
 1.40 </td>
<td align="center">
 8.92 </td>
</tr>
<tr class="Last">
<td>
 2 x 125 mg/5 mL </td>
<td align="center">
 2.37 </td>
<td align="center">
 3 </td>
<td align="center">
 1.44 </td>
<td align="center">
 9.75 </td>
</tr>
</tbody>
</table>
<p><a name="inv-75f64566-8aa5-459a-be37-9744b8d8e968"></a><span class="Sup">*</span>Mean values of 18 healthy adult volunteers</p>
<p><a name="inv-9f79756c-6835-4992-b8ed-9d4ed3d63c9f"></a><span class="Bold">Food Effect on Pharmacokinetics: </span>All pharmacokinetic and clinical effectiveness and safety studies in pediatric patients using the suspension formulation were conducted in the fed state. No data are available on the absorption kinetics of the suspension formulation when administered to fasted pediatric patients.</p>
<p><a name="inv-67d278ad-00fa-4e8d-882a-a3a30e05d006"></a><span class="Bold">Renal Excretion: </span>Cefuroxime is excreted unchanged in the urine; in adults, approximately 50% of the administered dose is recovered in the urine within 12 hours. The pharmacokinetics of cefuroxime in the urine of pediatric patients have not been studied at this time. Until further data are available, the renal pharmacokinetic properties of cefuroxime axetil established in adults should not be extrapolated to pediatric patients.</p>
<p><a name="inv-8939e0af-db71-4976-8291-2018bfbed904"></a>Because cefuroxime is renally excreted, the serum half-life is prolonged in patients with reduced renal function. In a study of 20 elderly patients (mean age = 83.9 years) having a mean creatinine clearance of 34.9 mL/min, the mean serum elimination half-life was 3.5 hours. Despite the lower elimination of cefuroxime in geriatric patients, dosage adjustment based on age is not necessary (see <span class="Bold">PRECAUTIONS: Geriatric Use</span>).</p>
<p><a name="inv-042d4d70-6f08-4f8e-83d6-d8f5fe2705ab"></a><span class="Bold">Microbiology: </span>The <span class="Italics">in vivo</span> bactericidal activity of cefuroxime axetil is due to cefuroxime's binding to essential target proteins and the resultant inhibition of cell-wall synthesis.</p>
<p><a name="inv-8534344f-37be-4fe2-b2f1-a82b313f860c"></a>Cefuroxime has bactericidal activity against a wide range of common pathogens, including many beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. Cefuroxime is stable to many bacterial beta-lactamases, especially plasmid-mediated enzymes that are commonly found in enterobacteriaceae. </p>
<p><a name="inv-d93d0d88-7969-410d-a6fc-e78f5a732f05"></a>Cefuroxime has been demonstrated to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold">INDICATIONS AND USAGE</span> section (see <span class="Bold">INDICATIONS AND USAGE</span> section).</p>
<p><a name="inv-74c9260a-9134-43b0-b5ff-2d6ca3b40c2f"></a><span class="Bold"><span class="Italics">Aerobic Gram-Positive Microorganisms:</span></span></p>
<p><a name="inv-e6be1f78-32b1-4014-8096-842601ae9e40"></a><span class="Italics">Staphylococcus aureus</span> (including beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><a name="inv-cb721357-71a3-4089-8429-c520e033157e"></a><span class="Italics">Streptococcus pneumoniae</span></p>
<p><a name="inv-55b00fd2-4737-427b-b504-173dac865460"></a><span class="Italics">Streptococcus pyogenes</span></p>
<p><a name="inv-690d98ba-3197-4392-9e7b-8da40549cd0a"></a><span class="Bold"><span class="Italics">Aerobic Gram-Negative Microorganisms:</span></span></p>
<p><a name="inv-50f822e7-913b-4fd2-bd75-17c090aa6c6e"></a><span class="Italics">Escherichia coli</span></p>
<p><a name="inv-5bfcebe4-e7fc-4913-8630-fe69327ed993"></a><span class="Italics">Haemophilus influenzae </span>(including beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><a name="inv-1005eda5-9008-4abc-85e1-b80e58c244e1"></a><span class="Italics">Haemophilus parainfluenzae</span></p>
<p><a name="inv-54578b8f-35dc-4453-a524-7f2bc7c00e58"></a><span class="Italics">Klebsiella pneumoniae</span></p>
<p><a name="inv-438efcbb-6d69-462e-9a35-269e7f046d55"></a><span class="Italics">Moraxella catarrhalis </span>(including beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><a name="inv-aa09b51a-5fe8-47bf-b808-722c54a79e77"></a><span class="Italics">Neisseria gonorrhoeae </span>(including beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><a name="inv-504b5333-40c5-449f-9f01-b841f8d4a497"></a><span class="Bold"><span class="Italics">Spirochetes:</span></span></p>
<p><a name="inv-d1b8d814-a70b-4d50-9701-baf98c98b94b"></a><span class="Italics">Borrelia burgdorferi</span></p>
<p><a name="inv-e7d18cd1-2441-4c6b-90a6-dea61027fef2"></a>Cefuroxime has been shown to be active <span class="Italics">in vitro</span> against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the clinical significance of these findings is unknown.</p>
<p><a name="inv-e2cc4a98-4618-498e-8259-25decd4340b0"></a>Cefuroxime exhibits <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) of 4 mcg/mL or less (systemic susceptible breakpoint) against most (<span class="Underline">&gt;</span> 90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and effectiveness of cefuroxime in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled trials.</p>
<p><a name="inv-06b1e2cd-ef00-4309-aae6-19b9ff96c956"></a><span class="Bold"><span class="Italics">Aerobic Gram-Positive Microorganisms:</span></span></p>
<p><a name="inv-1f34d08f-6307-47db-8998-d186a971bd5c"></a><span class="Italics">Staphylococcus epidermidis</span></p>
<p><a name="inv-d7cb63de-3669-46d4-9ade-f66c5eb8ff22"></a><span class="Italics">Staphylococcus saprophyticus</span></p>
<p><a name="inv-22b33090-c61a-4cfb-ae0f-289200d09ae9"></a><span class="Italics">Streptococcus agalactiae</span></p>
<p><a name="inv-dadb8985-dce1-4034-b177-fce8dcdf6902"></a>NOTE: <span class="Italics">Listeria monocytogenes</span> and certain <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterococci, e.g., <span class="Italics">Enterococcus faecalis</span> (formerly <span class="Italics">Streptococcus faecalis</span>), are resistant to cefuroxime. Methicillin-resistant staphylococci are resistant to cefuroxime.</p>
<p><a name="inv-e50d0eb2-6a73-4d86-a03c-84fb224222d8"></a><span class="Bold"><span class="Italics">Aerobic Gram-Negative Microorganisms:</span></span></p>
<p><a name="inv-3448dc09-4d5c-406d-937b-d013da5b722d"></a><span class="Italics">Morganella morganii</span></p>
<p><a name="inv-d57ec5a6-28c0-476f-979d-2e48e34e1b57"></a><span class="Italics">Proteus inconstans</span></p>
<p><a name="inv-c30626d0-2d5a-4382-87c1-d0d8c7c5404a"></a><span class="Italics">Proteus mirabilis</span></p>
<p><a name="inv-5825c7ac-28ef-422c-8ac9-dce21d55ca0c"></a><span class="Italics">Providencia rettgeri</span></p>
<p><a name="inv-97e09d4e-b10e-4ab6-9709-e22cd2c33576"></a>NOTE: <span class="Italics">Pseudomonas</span> spp., <span class="Italics">Campylobacter </span>spp., <span class="Italics">Acinetobacter</span><span class="Italics">calcoaceticus</span>, <span class="Italics">Legionella </span>spp., and most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Serratia</span> spp. and <span class="Italics">Proteus vulgaris</span> are resistant to most first- and second-generation cephalosporins. Some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Morganella</span><span class="Italics">morganii</span>, <span class="Italics">Enterobacter</span><span class="Italics">cloacae</span>, and <span class="Italics">Citrobacter</span> spp. have been shown by <span class="Italics">in vitro</span> tests to be resistant to cefuroxime and other cephalosporins.</p>
<p><a name="inv-e2ede8fe-a9cc-4de0-b4b2-a4710d504f7e"></a><span class="Bold"><span class="Italics">Anaerobic Microorganisms:</span></span></p>
<p><a name="inv-5fc0fe76-614f-46a3-b4a0-c6dcb4eabe8c"></a><span class="Italics">Peptococcus</span><span class="Italics">niger</span></p>
<p><a name="inv-5834af39-ba49-482d-ab5a-7f236bec8e03"></a>NOTE: Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Clostridium difficile</span> and <span class="Italics">Bacteroides fragilis</span> are resistant to cefuroxime.</p>
<p><a name="inv-3237461f-0d45-4ad5-8a9c-8eaf37c9a458"></a><span class="Bold">Susceptibility</span><span class="Bold">Tests: <span class="Italics">Dilution</span></span><span class="Italics"><span class="Bold">Techniques:</span></span> Quantitative methods that are used to determine MICs provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure uses a standardized dilution method<span class="Sup">1</span> (broth, agar, or microdilution) or equivalent with cefuroxime powder. The MIC values obtained should be interpreted according to the following criteria:</p>
<a name="inv-e718ed8a-2db9-4634-a4fb-98cd4a898192"></a><table frame="void">
<col width="304.00px">
<col width="256.00px">
<tbody class="Headless">
<tr class="First">
<td align="center"><span class="Underline">MIC (mcg/mL)</span></td>
<td align="center" valign="middle"><span class="Underline">Interpretation</span></td>
</tr>
<tr>
<td align="center">
 ≤ 4 </td>
<td align="center">
 (S) Susceptible </td>
</tr>
<tr>
<td align="center">
 8 to16  </td>
<td align="center">
 (I) Intermediate </td>
</tr>
<tr class="Last">
<td align="center">
 ≥ 32  </td>
<td align="center" valign="middle">
 (R) Resistant </td>
</tr>
</tbody>
</table>
<p><a name="inv-2b2d2f31-8885-48a0-86dd-a1039572de0f"></a>A report of "Susceptible" indicates that the pathogen, if in the blood, is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in blood. A report of "Intermediate" indicates that inhibitory concentrations of the antibiotic may be achieved if high dosage is used or if the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is confined to tissues or fluids in which high antibiotic concentrations are attained. This category also provides a buffer zone that prevents small, uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and that other therapy should be selected.</p>
<p><a name="inv-58742d05-de18-45d3-9405-e5514c151d7d"></a>Standardized susceptibility test procedures require the use of laboratory control microorganisms. Standard cefuroxime powder should give the following MIC values:</p>
<a name="inv-b9652ebe-b6bf-4456-a7b3-2bb4d71feb97"></a><table frame="void">
<col width="304.00px">
<col width="256.00px">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="middle"><span class="Underline">Microorganism</span></td>
<td align="center"><span class="Underline">MIC (mcg/mL)</span></td>
</tr>
<tr>
<td align="center">
<span class="Italics">Escherichia coli</span> ATCC 25922 </td>
<td align="center">
 2 to 8 </td>
</tr>
<tr class="Last">
<td align="center">
<span class="Italics">Staphylococcus aureus</span> ATCC 29213 </td>
<td align="center" valign="middle">
 0.5 to 2 </td>
</tr>
</tbody>
</table>
<p><a name="inv-fb0bcd6d-62a9-4d18-919c-777c20ab9ec2"></a><span class="Bold"><span class="Italics">Diffusion</span></span><span class="Italics"><span class="Bold">Techniques:</span></span> Quantitative methods that require measurement of zone diameters provide estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2</span> that has been recommended (for use with disks) to test the susceptibility of microorganisms to cefuroxime uses the 30 mcg cefuroxime disk. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for cefuroxime.</p>
<p><a name="inv-e8cbbdff-989f-42cf-ac34-ac626e38d449"></a>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 mcg cefuroxime disk should be interpreted according to the following criteria:</p>
<a name="inv-94da01dc-cc62-455f-86e3-be60d4c95240"></a><table frame="void">
<col width="296.00px">
<col width="264.00px">
<tbody class="Headless">
<tr class="First">
<td align="center"><span class="Underline">Zone Diameter (mm)</span></td>
<td align="center" valign="middle"><span class="Underline">Interpretation</span></td>
</tr>
<tr>
<td align="center">
 ≥ 23 </td>
<td align="center">
 (S) Susceptible </td>
</tr>
<tr>
<td align="center">
 15 to 22 </td>
<td align="center">
 (I) Intermediate </td>
</tr>
<tr class="Last">
<td align="center">
 ≤ 14 </td>
<td align="center" valign="middle">
 (R) Resistant </td>
</tr>
</tbody>
</table>
<p><a name="inv-a430c097-f269-45df-8f26-966a93c9ce4d"></a></p>
<p><a name="inv-fd5469c9-cb40-4193-be0c-e69930fb0cb5"></a>Interpretation should be as stated above for results using dilution techniques.</p>
<p><a name="inv-8047fad7-386a-4ce1-9845-ebedceb0adc4"></a>As with standard dilution techniques, diffusion methods require the use of laboratory control microorganisms. The 30 mcg cefuroxime disk provides the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<a name="inv-15a31ea8-df18-4a81-82c3-eda1b3aabc6e"></a><table border="1" frame="border">
<col width="300.00px">
<col width="288.00px">
<tbody class="Headless">
<tr class="First">
<td align="center"><span class="Underline">Microorganism</span></td>
<td align="center"><span class="Underline">Zone Diameter (mm)</span></td>
</tr>
<tr>
<td align="center">
<span class="Italics">Escherichia coli</span> ATCC 25922 </td>
<td align="center">
 20 to 26 </td>
</tr>
<tr class="Last">
<td align="center">
<span class="Italics">Staphylococcus aureus</span> ATCC 25923 </td>
<td align="center">
 27 to 35 </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="inv-14db9fa7-6a48-49a1-b28a-32755cf561ae"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><a name="inv-00aacaed-ebfc-4ac9-af2b-67d98087d8a2"></a><span class="Bold">NOTE: </span><span class="Bold">CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A</span><span class="Bold">MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY).</span></p>
<p><a name="inv-a3f8b152-9941-46e0-9e01-5e0da7653c3d"></a>Cefuroxime axetil for oral suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions listed below. The safety and effectiveness of cefuroxime axetil for oral suspension in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> other than those specifically listed below have not been established either by adequate and well-controlled trials or by pharmacokinetic data with which to determine an effective and safe dosing regimen.</p>
<ol class="Arabic">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span></span> caused by Streptococcus pyogenes. <span class="Bold">NOTE:</span> The usual drug of choice in the treatment and prevention of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, including the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>, is penicillin given by the intramuscular route. Cefuroxime axetil for oral suspension is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of Streptococcus pyogenes.</li>
<li>
<span class="Bold">Acute Bacterial <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></span> caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), Moraxella catarrhalis (including beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), or Streptococcus pyogenes.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">Impetigo</span></span> caused by Staphylococcus aureus (including beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) or Streptococcus pyogenes.</li>
</ol>
<p><a name="inv-3b1fb968-aebc-4ba5-b0cc-2bd8b849b41f"></a>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil for oral suspension and other antibacterial drugs, cefuroxime axetil for oral suspension should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="inv-b54588e3-59d7-40bb-9e04-23ae207d1939"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a name="inv-f292cfdf-88c9-46e4-8e2a-0bd454d670ea"></a>Cefuroxime axetil products are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to the cephalosporin group of antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="inv-af990a03-19e2-4427-818e-05baa04a11dd"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><a name="inv-fcdfa219-02d0-4497-a0f0-e4a3a865fb5b"></a><span class="Bold">CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE THEREFORE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY).</span></p>
<p><a name="inv-b2ff8d42-d575-4adb-b6a0-78bb30dfaf2a"></a><span class="Bold">BEFORE THERAPY WITH </span><span class="Bold">CEFUROXIME AXETIL PRODUCTS IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFUROXIME AXETIL PRODUCTS, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>. IF A CLINICALLY SIGNIFICANT <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFUROXIME AXETIL PRODUCTS OCCURS, DISCONTINUE THE DRUG AND INSTITUTE APPROPRIATE THERAPY. SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</span></p>
<p><a name="inv-0280031b-ca26-4585-a776-2812c2c5c365"></a><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including cefuroxime axetil for oral suspension, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile.</span></p>
<p><a name="inv-90f6fed1-8825-430d-b872-6bcc71cfb381"></a><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p><a name="inv-c27f49fd-c221-456e-8602-1d3490113342"></a>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="inv-1433c079-8130-41f7-907a-ed72d72f04e7"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="inv-28a1a80a-4d4c-4495-b682-07e92e95f3e8"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"><a name="inv-27f67d2b-87d0-47dc-a624-a325805e9b1f"></a>As with other broad-spectrum antibiotics, prolonged administration of cefuroxime axetil may result in overgrowth of nonsusceptible microorganisms. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.</p>
<p><a name="inv-8ac78e91-c224-455e-a12a-4333afb8ed2c"></a>Cephalosporins, including cefuroxime axetil, should be given with caution to patients receiving concurrent treatment with potent diuretics because these diuretics are suspected of adversely affecting renal function.</p>
<p><a name="inv-50f99b6f-feaa-4c8e-b0ec-83b04f6649c6"></a>Cefuroxime axetil, as with other broad-spectrum antibiotics, should be prescribed with caution in individuals with a history of <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. The safety and effectiveness of cefuroxime axetil have not been established in patients with gastrointestinal <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span>. Patients with gastrointestinal <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> were excluded from participating in clinical trials of cefuroxime axetil.</p>
<p><a name="inv-eba7b430-ec79-4c2a-a75f-d8aa3764209b"></a>Cephalosporins may be associated with a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity. Those at risk include patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be monitored in patients at risk and exogenous vitamin K administered as indicated.</p>
<p><a name="inv-0f4ce35c-50ce-47e1-85a7-39eef15ab3fe"></a>Prescribing cefuroxime axetil for oral suspension in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p><a name="inv-fe890fd2-41a4-4515-8055-3e7462687d4b"></a><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="inv-622dbd00-81b7-45b7-bdd1-5a92bb621b3e"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients/Caregivers (Pediatric)</h2>
<p class="First"><a name="inv-e7f7c992-e9bd-4959-9c7d-0dd9ef2bd1f5"></a><span class="Bold">Phenylketonurics: </span>Cefuroxime axetil for Oral Suspension 125 mg/5 ml and 250 mg/5 mL contain phenylalanine 4.5 mg per 5 mL (1 teaspoonful) constituted suspension.</p>
<p><a name="inv-3748e948-ae63-4acf-bdeb-36d942d492fa"></a>1. During clinical trials, the tablet was tolerated by pediatric patients old enough to swallow the cefuroxime axetil tablet whole. The crushed tablet has a strong, persistent, bitter taste and should not be administered to pediatric patients in this manner. Pediatric patients who cannot swallow the tablet whole should receive the oral suspension.</p>
<p><a name="inv-22e173f7-227c-47dc-ab86-56f56a29faac"></a>2. Discontinuation of therapy due to taste and/or problems of administering this drug occurred in 1.4% of pediatric patients given the oral suspension. Complaints about taste (which may impair compliance) occurred in 5% of pediatric patients.</p>
<p><a name="inv-2185d950-577a-4dcc-80ca-ab4e1e3ef5c7"></a>3. Patients should be counseled that antibacterial drugs, including cefuroxime axetil for oral suspension, should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When cefuroxime axetil for oral suspension is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefuroxime axetil for oral suspension or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="inv-69a5f2ad-3211-4930-a5fc-78cd10820e6d"></a><a name="section-7.3"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First"><a name="inv-b4a6e1f9-86c0-4b00-924b-46bb47b56fd1"></a>A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedict's or Fehling's solution or with CLINITEST<span class="Sup">®</span> tablets), but not with enzyme-based tests for <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> (e.g., CLINISTIX<span class="Sup">®</span>). As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil. The presence of cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="inv-452fe507-f66e-4fce-b23b-f778f83908b0"></a><a name="section-7.4"></a><p></p>
<h2>Drug/Drug Interactions</h2>
<p class="First"><a name="inv-cc8cef33-80cb-48e0-a244-aca6b5b6141f"></a>Concomitant administration of probenecid with cefuroxime axetil tablets increases the area under the serum concentration versus time curve by 50%. The peak serum cefuroxime concentration after a 1.5 g single dose is greater when taken with 1 g of probenecid (mean = 14.8 mcg/mL) than without probenecid (mean = 12.2 mcg/mL).</p>
<p><a name="inv-54716f26-ef08-49ad-8180-9c13f1bf3599"></a>Drugs that reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with that of fasting state and tend to cancel the effect of postprandial absorption.</p>
<p><a name="inv-dc5a151d-e347-40ed-8152-07415993ec12"></a>In common with other antibiotics, cefuroxime axetil may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="inv-4999d8cb-1bde-401d-b72b-8c61792eb85c"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First"><a name="inv-d710bb8c-6071-4a2e-8605-5f2950dc06b2"></a>Although lifetime studies in animals have not been performed to evaluate carcinogenic potential, no mutagenic activity was found for cefuroxime axetil in a battery of bacterial mutation tests. Positive results were obtained in an <span class="Italics">in vitro </span>chromosome aberration assay, however, negative results were found in an <span class="Italics">in vivo </span>micronucleus test at doses up to 1.5 g/kg. Reproduction studies in rats at doses up to 1,000 mg/kg/day (9 times the recommended maximum human dose based on mg/m<span class="Sup">2</span>) have revealed no impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="inv-7969add8-7135-476a-9028-5b18f7d994da"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><a name="inv-a07aee9b-fb53-425d-86cd-6b4f5c863744"></a><span class="Bold"><span class="Italics">Teratogenic Effects:</span></span> Pregnancy Category B. Reproduction studies have been performed in mice at doses up to 3,200 mg/kg/day (14 times the recommended maximum human dose based on mg/m<span class="Sup">2</span>) and in rats at doses up to 1,000 mg/kg/day (9 times the recommended maximum human dose based on mg/m<span class="Sup">2</span>) and have revealed no evidence of impaired fertility or harm to the fetus due to cefuroxime axetil. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="inv-1e808c24-f2ba-46fe-9828-3f4c75216eab"></a><a name="section-7.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First"><a name="inv-490e7abf-3717-4562-b4b9-db7e25d27fe6"></a>Cefuroxime axetil has not been studied for use during labor and delivery.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="inv-1ed22c9d-54a3-42e6-b8a9-f94a38c847e9"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"><a name="inv-801a0bc0-98ff-4227-beee-f18c010fc3e3"></a>Because cefuroxime is excreted in human milk, consideration should be given to discontinuing nursing temporarily during treatment with cefuroxime axetil.</p>
<p><a name="inv-e61df71e-8f39-46b9-bacd-b78207517a7e"></a></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="inv-a28bc5de-4193-40f3-96bf-384caeec77a7"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><a name="inv-d6502cff-fce4-48f6-aff3-feab0cf4695a"></a>The safety and effectiveness of cefuroxime axetil have been established for pediatric patients aged 3 months to 12 years for acute bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span> based upon its approval in adults. Use of cefuroxime axetil in pediatric patients is supported by pharmacokinetic and safety data in adults and pediatric patients, and by clinical and microbiological data from adequate and well-controlled studies of the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span> in adults and of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> with <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusion</span> in pediatric patients. It is also supported by postmarketing adverse events surveillance (see <span class="Bold">CLINICAL PHARMACOLOGY, INDICATIONS AND USAGE, ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION</span>, and<span class="Bold"> CLINICAL STUDIES</span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="inv-5caceabe-68ae-432a-b869-4181611922d3"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First"><a name="inv-e849ec2c-0c20-442e-8819-c2351fac2380"></a>Of the total number of subjects who received cefuroxime axetil in 20 clinical studies of cefuroxime axetil, 375 were 65 and over while 151 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger adult subjects. The geriatric patients reported somewhat fewer gastrointestinal events and less frequent <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span> compared with patients aged 12 to 64 years old; however, no clinically significant differences were reported between the elderly and younger adult patients. Other reported clinical experience has not identified differences in responses between the elderly and younger adult patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="inv-1779ed67-ceb3-41bf-b94e-e96da6c959a3"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><a name="inv-37d7d319-cc9d-4693-a316-58ca7830331b"></a>In clinical trials using multiple doses of cefuroxime axetil powder for oral suspension, pediatric patients (96.7% of whom were younger than 12 years of age) were treated with the recommended dosages of cefuroxime axetil (20 to 30 mg/kg/day divided twice a day up to a maximum dose of 500 or 1,000 mg/day, respectively). There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> or permanent disabilities in any of the patients in these studies. Eleven U.S. patients (1.2%) discontinued medication due to adverse events thought by the investigators to be possibly, probably, or almost certainly related to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span>. The discontinuations were primarily for <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, usually <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. During clinical trials, discontinuation of therapy due to the taste and/or problems with administering this drug occurred in 13 (1.4%) pediatric patients enrolled at centers in the United States.</p>
<p><a name="inv-a20543f4-241a-4b39-be38-358257c7a116"></a>The following adverse events were thought by the investigators to be possibly, probably, or almost certainly related to cefuroxime axetil for oral suspension in multiple-dose clinical trials (n = 931 cefuroxime axetil-treated U.S. patients).</p>
<a name="inv-6d74ac95-ba06-4cd7-878b-32fe3c0ec0f6"></a><table border="1" frame="border">
<caption><span>Table 3: Adverse Reactions—Cefuroxime Axetil For Oral Suspension Multiple-Dose Dosing Regimens—Clinical Trials</span></caption>
<col width="228.00px">
<col width="228.00px">
<col width="168.00px">
<tbody class="Headless">
<tr class="First">
<td>
 Incidence ≥ 1% </td>
<td>
 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> </td>
<td align="center">
 8.6% </td>
</tr>
<tr>
<td></td>
<td>
 Dislike of taste </td>
<td align="center">
 5 % </td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">Diaper rash</span> </td>
<td align="center">
 3.4% </td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </td>
<td align="center">
 2.6% </td>
</tr>
<tr>
<td>
 Incidence &lt; 1% but &gt; 0.1% </td>
<td>
 <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 Gastrointestinal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candidiasis</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="4058568" conceptname="Vaginal irritation">Vaginal irritation</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritable</span> behavior </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 Positive direct Coombs’ test </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 Elevated liver enzymes  </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 Viral illness </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory infection</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">Joint swelling</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </td>
<td align="center"></td>
</tr>
<tr>
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </td>
<td align="center"></td>
</tr>
<tr class="Last">
<td></td>
<td>
 <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Ptyalism</span> </td>
<td align="center"></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="34084-4">
<a name="inv-7143d67d-3756-41b6-af20-1814c1d677a7"></a><a name="section-8.1"></a><p></p>
<h2>POSTMARKETING EXPERIENCE WITH CEFUROXIME AXETIL PRODUCTS</h2>
<p class="First"><a name="inv-6ebfa10b-3a12-40e0-a84b-b3261f9b7987"></a>In addition to adverse events reported during clinical trials, the following events have been identified during clinical practice in patients treated with cefuroxime tablets or with cefuroxime axetil for oral suspension and were reported spontaneously. Data are generally insufficient to allow an estimate of incidence or to establish causation. </p>
<p><a name="inv-85d30657-b380-407f-b133-c0f434bb08d5"></a><span class="Bold"><span class="Italics">General:</span></span>The following <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like reaction, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><a name="inv-4db9c838-1f01-44f8-ac6e-8bb071f8a751"></a><span class="Bold"><span class="Italics">Gastrointestinal:</span></span> <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> (see <span class="Bold">WARNINGS</span>).</p>
<p><a name="inv-66efcc2a-a192-49be-8754-fa290407375f"></a><span class="Bold"><span class="Italics">Hematologic: </span></span><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
<p><a name="inv-6c7a9ac4-8663-4ab9-bfdd-d03fbd573dae"></a><span class="Bold"><span class="Italics">Hepatic:</span></span> <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span> including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p><a name="inv-5454c0bb-f94b-4871-b07a-7ab518f4f218"></a><span class="Bold"><span class="Italics">Neurologic:</span></span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>.</p>
<p><a name="inv-f783cd46-8505-4ee3-bf6a-a36490302c94"></a><span class="Bold"><span class="Italics">Skin:</span></span><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
<p><a name="inv-f1d68645-7a46-4017-989f-cec235ac37d0"></a><span class="Bold"><span class="Italics">Urologic:</span></span> Renal dysfunction.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="inv-5e1e53bd-1586-42c2-a04d-e5a7a77c0369"></a><a name="section-8.2"></a><p></p>
<h2>CEPHALOSPORIN-CLASS ADVERSE REACTIONS</h2>
<p class="First"><a name="inv-fffa091c-aa7f-43b7-9573-2ceafd2733b2"></a>In addition to the adverse reactions listed above that have been observed in patients treated with cefuroxime axetil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>,  <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, increased BUN, increased creatinine, false-positive test for urinary glucose, increased alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, elevated bilirubin, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. </p>
<p><a name="inv-3f2527b4-6ffc-4228-a285-49d1d49c91bc"></a>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when the dosage was not reduced (see <span class="Bold">DOSAGE AND ADMINISTRATION </span>and<span class="Bold"> OVERDOSAGE</span>). If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="inv-94c692be-85a4-4fdd-bd85-d430bf1139a1"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><a name="inv-fb0d7517-756a-4b1c-bcef-2b3258bc55c1"></a>Overdosage of cephalosporins can cause cerebral irritation leading to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Serum levels of cefuroxime can be reduced by hemodialysis and peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="inv-f35f21c5-6386-4813-8e37-da007a1ef68e"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><a name="inv-8ee429f3-623f-408e-8379-476d3a1fb64c"></a><span class="Bold">NOTE: </span><span class="Bold">CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A </span><span class="Bold">MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY).</span></p>
<p><a name="inv-2ead2c9c-cb9e-4be0-a1b3-af51da3b5af1"></a>Cefuroxime axetil for oral suspension may be administered to pediatric patients ranging in age from 3 months to 12 years, according to dosages in <span class="Bold">Table 4</span>:</p>
<a name="inv-07f73602-ebde-4658-be8b-a2cf8d7847be"></a><table border="1" frame="border">
<caption><span>Table 4: Cefuroxime Axetil For Oral Suspension(Must be administered with food. Shake well each time before using.)</span></caption>
<col width="188.00px">
<col width="168.00px">
<col width="136.00px">
<col width="112.00px">
<tbody class="Headless">
<tr class="First">
<td align="center">
 Population/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </td>
<td align="center">
 Dosage </td>
<td align="center">
 Daily Maximum
 Dose </td>
<td align="center">
 Duration
 (days) </td>
</tr>
<tr><td colspan="4"><span class="Bold">Pediatric Patients  (3 months to 12 years)</span></td></tr>
<tr>
<td>
 <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> </td>
<td>
 20 mg/kg/day divided b.i.d. </td>
<td align="center">
 500 mg </td>
<td align="center">
 10 </td>
</tr>
<tr>
<td>
 Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> </td>
<td>
 30 mg/kg/day divided b.i.d. </td>
<td align="center">
 1,000 mg </td>
<td align="center">
 10 </td>
</tr>
<tr>
<td>
 Acute bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span> </td>
<td>
 30 mg/kg/day divided b.i.d. </td>
<td align="center">
 1,000 mg </td>
<td align="center">
 10 </td>
</tr>
<tr class="Last">
<td>
 <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">Impetigo</span>  </td>
<td>
 30 mg/kg/day divided b.i.d. </td>
<td align="center">
 1,000 mg </td>
<td align="center">
 10 </td>
</tr>
</tbody>
</table>
<p><a name="inv-931e4a11-0ae9-4009-9005-82c435744806"></a><span class="Bold">Patients With <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span>:</span> The safety and efficacy of cefuroxime axetil in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> have not been established. Since cefuroxime is renally eliminated, its half-life will be prolonged in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
<p><a name="inv-9945b70c-b163-44af-afee-d5b27d7e08f1"></a><span class="Bold">Directions for Mixing </span><span class="Bold">Cefuroxime Axetil For Oral Suspension:</span> Prepare a suspension at the time of dispensing as follows:</p>
<p><a name="inv-2f894c69-2972-4062-a8ab-1fb78e7fc571"></a>1. Shake the bottle to loosen the powder. </p>
<p><a name="inv-ec3bfe36-60f3-469b-89f1-e2739b763ef3"></a>2. Remove the cap. </p>
<p><a name="inv-4111eee3-bef2-43de-9ae4-5c31edbff809"></a>3. Add the total amount of water for reconstitution (see <span class="Bold">Table 5</span>) and replace the cap. </p>
<p><a name="inv-a9da76d9-ce0a-434f-bf4d-d9fdbf2b7a21"></a>4. Vigorously shake in a diagonal direction to form suspension. </p>
<a name="inv-ababa72f-4ab4-4c45-a56e-8c73ac00c5d8"></a><table border="1" frame="border">
<caption><span>Table 5: Amount of Water Required for Reconstitution of Labeled Volumes of Cefuroxime Axetil For Oral Suspension</span></caption>
<col width="196.00px">
<col width="204.00px">
<col width="220.00px">
<tbody class="Headless">
<tr class="First">
<td align="center">
 Cefuroxime Axetil for Oral 
 Suspension </td>
<td align="center">
 Labeled Volume After
 Reconstitution </td>
<td align="center">
 Amount of Water Required
 for Reconstitution </td>
</tr>
<tr>
<td align="center" rowspan="2">
 125 mg/5 mL </td>
<td align="center">
 50 mL </td>
<td align="center">
 23 mL </td>
</tr>
<tr>
<td align="center">
 100 mL </td>
<td align="center">
 44 mL </td>
</tr>
<tr>
<td align="center" rowspan="2">
 250 mg/5 mL </td>
<td align="center">
 50 mL </td>
<td align="center">
 22 mL </td>
</tr>
<tr class="Last">
<td align="center">
 100 mL </td>
<td align="center">
 43 mL </td>
</tr>
</tbody>
</table>
<p><a name="inv-f6457010-bb58-4def-be2f-2cf4b7679d49"></a><span class="Bold">NOTE: SHAKE THE ORAL SUSPENSION WELL BEFORE EACH USE.</span> Replace cap securely after each opening. Store the reconstituted suspension between 2 and 8°C (36 and 46°F) (in the refrigerator). DISCARD AFTER 10 DAYS.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="inv-e1490498-66ea-420b-a483-24ded48350a0"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><a name="inv-e922fef4-a5b5-4b8e-8376-4036ed16be24"></a><span class="Bold">Cefuroxime Axetil For Oral Suspension USP:</span> When reconstituted as directed, cefuroxime axetil for oral suspension USP provides the equivalent of 125 mg or 250 mg of cefuroxime (as cefuroxime axetil) per 5 mL of suspension. It is supplied as follows:</p>
<p><a name="inv-fdf99f2a-fa5a-4a82-9cba-8e0210179bb2"></a><span class="Bold">The 125 mg/5 mL: </span>is a white to cream colored granular powder forming white to cream colored suspension on constitution with water. The resulting suspension has a fruity flavor.</p>
<p><a name="inv-e78e8b72-123b-46d3-b5f7-f941ff85f984"></a>NDC 63304-963-03 50 mL bottles</p>
<p><a name="inv-a649a8d0-0cfa-4445-95a7-42f51948d707"></a>NDC 63304-963-04 100 mL bottles</p>
<p><a name="inv-ffb984e9-36e9-4abc-ae87-c8d298d0910d"></a><span class="Bold">The 250 mg/5 mL:</span> is a white to cream colored granular powder forming white to cream colored suspension on constitution with water. The resulting suspension has a fruity flavor.</p>
<p><a name="inv-b44e2d81-ec76-4085-b5e7-0897f207326a"></a>NDC 63304-964-03 50 mL bottles</p>
<p><a name="inv-161cb593-b66a-4afc-b25b-c4b3a0dbf85d"></a>NDC 63304-964-04 100 mL bottles</p>
<p><a name="inv-54067666-d49e-4a79-aa1f-5cd6f6dbd013"></a><span class="Bold">Before reconstitution, store dry powder between 20 - 25° C (68 - 77° F). (See USP Controlled Room Temperature)</span></p>
<p><a name="inv-0e220010-f05b-4feb-b51e-dea564751183"></a><span class="Bold">After reconstitution, immediately store suspension between 2 - 8</span>° <span class="Bold">C (36 - 46</span>° <span class="Bold">F), in a refrigerator. DISCARD AFTER 10 DAYS.</span></p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="inv-ec648dc2-4472-4a27-967d-1da90c014826"></a><a name="section-12"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"><a name="inv-1b091545-354d-4ae7-91d9-95a663f3556d"></a><span class="Bold">Cefuroxime Axetil Tablets:</span><span class="Bold"><span class="Italics">Acute Bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">Maxillary Sinusitis</span></span></span>: One adequate and well-controlled study was performed in patients with acute bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span>. In this study each patient had a maxillary sinus aspirate collected by sinus puncture before treatment was initiated for presumptive acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>. All patients had to have radiographic and clinical evidence of <span class="product-label-link" type="condition" conceptid="141323" conceptname="Acute maxillary sinusitis">acute maxillary sinusitis</span>. As shown in the following summary of the study, the general clinical effectiveness of cefuroxime axetil tablets was comparable to an oral antimicrobial agent that contained a specific beta-lactamase inhibitor in treating <span class="product-label-link" type="condition" conceptid="141323" conceptname="Acute maxillary sinusitis">acute maxillary sinusitis</span>. However, sufficient microbiology data were obtained to demonstrate the effectiveness of cefuroxime axetil tablets in treating acute bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span> due only to <span class="Italics">Streptococcus pneumoniae</span> or non-beta-lactamase-producing <span class="Italics">Haemophilus influenzae</span>. An insufficient number of beta-lactamase- producing <span class="Italics">Haemophilus influenzae</span> and <span class="Italics">Moraxella catarrhalis</span> isolates were obtained in this trial to adequately evaluate the effectiveness of cefuroxime axetil tablets in the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">maxillary sinusitis</span> due to these 2 organisms.</p>
<p><a name="inv-537986ad-fc6a-4ee2-8e36-4d45c29d4c5e"></a>This study enrolled 317 adult patients, 132 patients in the United States and 185 patients in South America. Patients were randomized in a 1:1 ratio to cefuroxime axetil 250 mg twice daily or an oral antimicrobial agent that contained a specific beta-lactamase inhibitor. An intent-to-treat analysis of the submitted clinical data yielded the following results:</p>
<a name="inv-b2fc2ea1-e9f0-4d23-a2f1-556eb7404b7b"></a><table border="1" frame="border">
<caption><span>Table 6: Clinical Effectiveness of Cefuroxime Axetil Tablets Compared to Beta-Lactamase Inhibitor-Containing Control Drug in the Treatment of Acute Bacterial <span class="product-label-link" type="condition" conceptid="4228816" conceptname="Maxillary sinusitis">Maxillary Sinusitis</span></span></caption>
<col width="180.00px">
<col width="120.00px">
<col width="96.00px">
<col width="132.00px">
<col width="88.00px">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"></td>
<td align="center" colspan="2" valign="middle">
 U.S. Patients<span class="Sup">*</span>
</td>
<td align="left" colspan="2" valign="top">
 South American Patients<span class="Sup">†</span>
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">
 Cefuroxime Axetil
 (n = 49) </td>
<td align="left" valign="top">
 Control
 (n = 43) </td>
<td align="left" valign="top">
 Cefuroxime
 Axetil 
 (n = 87) </td>
<td align="left" valign="top">
 Control
 (n = 89) </td>
</tr>
<tr>
<td align="left" valign="top">
 Clinical success
 (cure + improvement) </td>
<td align="left" valign="top">
 65% </td>
<td align="left" valign="top">
 53% </td>
<td align="left" valign="top">
 77% </td>
<td align="left" valign="top">
 74% </td>
</tr>
<tr>
<td align="left" valign="top">
 Clinical cure </td>
<td align="left" valign="top">
 53% </td>
<td align="left" valign="top">
 44% </td>
<td align="left" valign="top">
 72% </td>
<td align="left" valign="top">
 64% </td>
</tr>
<tr class="Last">
<td align="left" valign="top">
 Clinical improvement </td>
<td align="left" valign="top">
 12% </td>
<td align="left" valign="top">
 9% </td>
<td align="left" valign="top">
 5% </td>
<td align="left" valign="top">
 10% </td>
</tr>
</tbody>
</table>
<p><a name="inv-b160a03d-fd73-4ce7-908a-e0d9b4bbd41d"></a><span class="Sup">*</span> 95% Confidence interval around the success difference [-0.08, +0.32].</p>
<p><a name="inv-03ba111f-b91d-4fdc-9f3b-2b501ba3de8b"></a><span class="Sup">†</span> 95% Confidence interval around the success difference [-0.10, +0.16].</p>
<p><a name="inv-242529ab-e2c1-4508-83fb-ca4f064d6bd4"></a>In this trial and in a supporting maxillary puncture trial, 15 evaluable patients had non-beta-lactamase-producing <span class="Italics">Haemophilus influenzae</span> as the identified pathogen. Ten (10) of these 15 patients (67%) had their pathogen (non-beta-lactamase-producing <span class="Italics">Haemophilus influenzae</span>) eradicated. Eighteen (18) evaluable patients had <span class="Italics">Streptococcus pneumoniae</span> as the identified pathogen. Fifteen (15) of these 18 patients (83%) had their pathogen (<span class="Italics">Streptococcus pneumoniae</span>) eradicated.</p>
<p><a name="inv-ae079c41-17c5-4dcb-8c4e-17fe1ace26b6"></a><span class="Bold"><span class="Italics">Safety:</span></span> The incidence of drug-related gastrointestinal adverse events was statistically significantly higher in the control arm (an oral antimicrobial agent that contained a specific beta-lactamase inhibitor) versus the cefuroxime axetil arm (12% versus 1%, respectively; <span class="Italics">P </span>&lt; .001), particularly drug-related <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (8% versus 1%, respectively; <span class="Italics">P </span>= .001).</p>
<p><a name="inv-5e9a7051-94e9-4edf-bdad-870a16c0bb0a"></a><span class="Bold"><span class="Italics">Early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme Disease</span>:</span></span> Two adequate and well-controlled studies were performed in patients with early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span>. In these studies all patients had to present with physician-documented <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> migrans, with or without systemic manifestations of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Patients were randomized in a 1:1 ratio to a 20-day course of treatment with cefuroxime axetil 500 mg twice daily or doxycycline 100 mg 3 times daily. Patients were assessed at 1 month posttreatment for success in treating early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span> (Part I) and at 1 year posttreatment for success in preventing the progression to the sequelae of late <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span> (Part II).</p>
<p><a name="inv-c84dbb65-6831-45cc-96de-56f180fc6083"></a>A total of 355 adult patients (181 treated with cefuroxime axetil and 174 treated with doxycycline) were enrolled in the 2 studies. In order to objectively validate the clinical diagnosis of early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span> in these patients, 2 approaches were used: 1) blinded expert reading of photographs, when available, of the pretreatment <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> migrans <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesion</span>; and 2) serologic confirmation (using enzyme-linked immunosorbent assay [ELISA] and immunoblot assay [“Western? blot]) of the presence of antibodies specific to <span class="Italics">Borrelia burgdorferi</span>, the etiologic agent of <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span>. By these procedures, it was possible to confirm the physician diagnosis of early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span> in 281 (79%) of the 355 study patients. The efficacy data summarized below are specific to this “validated? patient subset, while the safety data summarized below reflect the entire patient population for the 2 studies.</p>
<p><a name="inv-bf6d80f6-cdb5-4801-91bf-b1f8c2ba2c78"></a>Analysis of the submitted clinical data for evaluable patients in the “validated? patient subset yielded the following results:</p>
<a name="inv-cc1cf2eb-912a-4334-8b59-c322ea57c756"></a><table border="1" frame="border">
<caption><span>Table 7: Clinical Effectiveness of Cefuroxime Axetil Tablets Compared to Doxycycline in the Treatment of Early <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme Disease</span></span></caption>
<col width="192.00px">
<col width="100.00px">
<col width="108.00px">
<col width="98.00px">
<col width="104.00px">
<tbody class="Headless">
<tr class="First">
<td></td>
<td align="center" colspan="2">
 Part I
 (1 Month Posttreatment)<span class="Sup">*</span>
</td>
<td align="center" colspan="2">
 Part II
 (1 Year Posttreatment)<span class="Sup">†</span>
</td>
</tr>
<tr>
<td></td>
<td>
 Cefuroxime Axetil </td>
<td>
 Doxycycline  </td>
<td>
 Cefuroxime Axetil </td>
<td>
 Doxycycline </td>
</tr>
<tr>
<td></td>
<td>
 (n = 125) </td>
<td>
 (n = 108) </td>
<td>
 (n = 105<span class="Sup">‡</span>) </td>
<td>
 (n = 83<span class="Sup">‡</span>) </td>
</tr>
<tr>
<td>
 Satisfactory clinical outcome<span class="Sup">§</span>
</td>
<td>
 91% </td>
<td>
 93% </td>
<td>
 84% </td>
<td>
 87% </td>
</tr>
<tr>
<td>
 Clinical cure/success  </td>
<td>
 72% </td>
<td>
 73% </td>
<td>
 73% </td>
<td>
 73% </td>
</tr>
<tr class="Last">
<td>
Clinical improvement </td>
<td>
 19% </td>
<td>
 19% </td>
<td>
 10% </td>
<td>
 13% </td>
</tr>
</tbody>
</table>
<p><a name="inv-a91671f7-1aea-4fd4-b6f1-16076b6904ea"></a><span class="Sup">*</span> 95% confidence interval around the satisfactory difference for Part I (-0.08, +0.05).</p>
<p><a name="inv-02ca16f0-2618-4161-8e47-4571ebcdde60"></a><span class="Sup">†</span> 95% confidence interval around the satisfactory difference for Part II (-0.13, +0.07).</p>
<p><a name="inv-2aa641a4-877b-4cd4-87ad-ec6558650cd4"></a><span class="Sup">‡</span> n’s include patients assessed as unsatisfactory clinical outcomes (failure + recurrence) in Part I (cefuroxime axetil - 11 [5 failure, 6 recurrence]; doxycycline - 8 [6 failure, 2 recurrence]).</p>
<p><a name="inv-df5e12c0-d678-4009-95d3-4580604d03a8"></a><span class="Sup">§</span> Satisfactory clinical outcome includes cure + improvement (Part I) and success + improvement (Part II).</p>
<p><a name="inv-92c62a8a-dd91-4dfa-b0d5-816069332c04"></a>Cefuroxime axetil and doxycycline were effective in prevention of the development of sequelae of late <span class="product-label-link" type="condition" conceptid="440638" conceptname="Lyme disease">Lyme disease</span>.</p>
<p><a name="inv-fb22323b-1219-4cd9-99d5-ee127d5be83c"></a><span class="Bold"><span class="Italics">Safety: </span></span>Drug-related adverse events affecting the skin were reported significantly more frequently by patients treated with doxycycline than by patients treated with cefuroxime axetil (12% versus 3%, respectively; <span class="Italics">P </span>= .002), primarily reflecting the statistically significantly higher incidence of drug-related <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span> in the doxycycline arm versus the cefuroxime axetil arm (9% versus 0%, respectively; <span class="Italics">P </span>&lt; .001). While the incidence of drug-related gastrointestinal adverse events was similar in the 2 treatment groups (cefuroxime axetil - 13%; doxycycline - 11%), the incidence of drug-related <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was statistically significantly higher in the cefuroxime axetil arm versus the doxycycline arm (11% versus 3%, respectively; <span class="Italics">P </span>= .005).</p>
<p><a name="inv-e32e93df-1599-4ce5-9592-a826ed77f993"></a><span class="Bold"><span class="Italics">Secondary <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infections</span> of <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Acute Bronchitis</span>:</span></span> Four randomized, controlled clinical studies were performed comparing 5 days versus 10 days of cefuroxime axetil for the treatment of patients with secondary <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> of <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">acute bronchitis</span>. These studies enrolled a total of 1,253 patients (CAE-516 n = 360; CAE-517 n = 177; CAEA4001 n = 362; CAEA4002 n = 354). The protocols for CAE-516 and CAE-517 were identical and compared cefuroxime axetil 250 mg twice daily for 5 days, cefuroxime axetil 250 mg twice daily for 10 days, and AUGMENTIN<span class="Sup">®</span> 500 mg 3 times daily for 10 days. These 2 studies were conducted simultaneously. CAEA4001 and CAEA4002 compared cefuroxime axetil 250 mg twice daily for 5 days, cefuroxime axetil 250 mg twice daily for 10 days, and CECLOR<span class="Sup">®</span> 250 mg 3 times daily for 10 days. They were otherwise identical to CAE-516 and CAE-517 and were conducted over the following 2 years.  Patients were required to have polymorphonuclear cells present on the Gram stain of their screening <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> specimen, but isolation of a bacterial pathogen from the <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> culture was not required for inclusion. The following table demonstrates the results of the clinical outcome analysis of the pooled studies CAE-516/CAE-517 and CAEA4001/CAEA4002, respectively:</p>
<a name="inv-063ad20b-af08-4b42-9d39-4c644a337982"></a><table border="1" frame="border">
<caption><span>Table 8: Clinical Effectiveness of Cefuroxime Axetil Tablets 250 mg Twice Daily in Secondary <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infections</span> of <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Acute Bronchitis</span>: Comparison of 5 Versus 10 Days’ Treatment Duration</span></caption>
<col width="222.00px">
<col width="108.00px">
<col width="100.00px">
<col width="96.00px">
<col width="84.00px">
<tbody class="Headless">
<tr class="First">
<td></td>
<td colspan="2">
 CAE-516 and CAE-517<span class="Sup">*</span>
</td>
<td colspan="2">
 CAEA4001 and CAEA4002<span class="Sup">†</span>
</td>
</tr>
<tr>
<td></td>
<td align="center">
 5 Day
 (n = 127) </td>
<td align="center">
 10 Day
 (n = 139) </td>
<td align="center">
 5 Day
 (n = 173) </td>
<td align="center">
 10 Day
 (n = 192) </td>
</tr>
<tr>
<td>
Clinical success (cure + improvement)  </td>
<td>
 80% </td>
<td>
 87% </td>
<td>
 84% </td>
<td>
 82% </td>
</tr>
<tr>
<td>
 Clinical cure  </td>
<td>
 61% </td>
<td>
 70% </td>
<td>
 73% </td>
<td>
 72% </td>
</tr>
<tr class="Last">
<td>
 Clinical improvement </td>
<td>
 19% </td>
<td>
 17% </td>
<td>
 11% </td>
<td>
 10% </td>
</tr>
</tbody>
</table>
<p><a name="inv-e62ad3f8-327d-4799-9b34-9ca389ec85b3"></a><span class="Sup">*</span> 95% Confidence interval around the success difference [-0.164, +0.029].</p>
<p><a name="inv-20a3a64e-687a-4263-bcce-7ad89c82ace3"></a><span class="Sup">†</span> 95% Confidence interval around the success difference [-0.061, +0.103].</p>
<p><a name="inv-6f9b93d0-b94e-4649-969c-31473f18eeb3"></a>The response rates for patients who were both clinically and bacteriologically evaluable were consistent with those reported for the clinically evaluable patients.</p>
<p><a name="inv-512968e9-2259-44f2-a9ed-69f879bea9c4"></a><span class="Bold"><span class="Italics">Safety:</span></span> In these clinical trials, 399 patients were treated with cefuroxime axetil for 5 days and 402 patients with cefuroxime axetil for 10 days. No difference in the occurrence of adverse events was observed between the 2 regimens.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="inv-1e5df153-8a65-4c19-8939-9e28f4003dba"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"><a name="inv-b7115f95-17d9-4bb7-b73a-e6abb0bcad3a"></a>1. National Committee for Clinical Laboratory Standards. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically</span>. 3rd ed. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25. Villanova, Pa: NCCLS; 1993.</p>
<p><a name="inv-36d1c7c0-4647-4062-83f1-a9a8bc9a33b5"></a>2. National Committee for Clinical Laboratory Standards. <span class="Italics">Performance Standards for </span><span class="Italics">Antimicrobial Disk Susceptibility Tests</span>. 4th ed. Approved Standard NCCLS Document M2-A4, Vol. 10, No. 7. Villanova, Pa: NCCLS; 1990.</p>
<p><a name="inv-2672e095-7117-4627-a2fd-ac535be13207"></a>CLINITEST and CLINISTIX are registered trademarks of Ames Division, Miles Laboratories, Inc.</p>
<p><a name="inv-1d0ae90c-85fd-4a4e-8d7f-4e2a58cb7ef0"></a>CECLOR<span class="Sup">®</span> is a registered trademark of Lilly.</p>
<p><a name="inv-5987cfb7-9a81-4a0d-bc01-537852f96704"></a>AUGMENTIN<span class="Sup">®</span> is a registered trademark of GlaxoSmithKline</p>
<p><a name="inv-a18bde5b-4fee-4cea-b19a-ef3089d514fe"></a>Manufactured for:</p>
<p><a name="inv-a60330a6-0233-4da4-adf3-a542bd767209"></a>Ranbaxy Pharmaceuticals Inc.</p>
<p><a name="inv-d50d8128-ef76-40a2-88ad-f0e3f298a271"></a>Jacksonville, FL 32257 USA</p>
<p><a name="inv-b6f218ca-2157-4232-a5fa-530319afdfc8"></a>by: Ranbaxy Laboratories Limited</p>
<p><a name="inv-c0263176-6a50-4667-a117-0d0cb078cff1"></a>New Delhi - 110 019, India</p>
<p><a name="inv-771998a3-3163-4055-9dc3-1544e48d8845"></a>September 2007 </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-3743c526-941a-4add-9d6d-954c9564a691"></a><a name="section-14"></a><p></p>
<h1>PACKAGE LABEL. PRINCIPAL DISPLAY PANEL. </h1>
<p class="First"><a name="inv-7c5559eb-c683-4592-bfa9-ce17fd6d03c0"></a>RANBAXY</p>
<p><a name="inv-c28dded8-ccd3-41ec-a611-0492ba088ef0"></a>NDC 63304-963-04</p>
<p><a name="inv-d36ce10f-d319-4e61-88e6-b89b04876954"></a>CEFUROXIME AXETIL FOR ORAL SUSPENSION, USP</p>
<p><a name="inv-f23193a1-746b-4208-8ec8-6125f2ef36b3"></a>Rx only				100 ml</p>
<div class="Figure">
<a name="ID0E1CBG"></a><img alt="label001" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=135e2dfc-eb47-4d04-a903-a081d36c267e&amp;name=label001.jpg"><p class="MultiMediaCaption">125 mg-5 ml bottle label</p>
</div>
<p><a name="inv-429c73bc-b038-4b5c-a39e-8a1c23888eb8"></a>RANBAXY</p>
<p><a name="inv-3d5660f3-06bf-4739-87e8-c86f2ea5ba3e"></a> NDC 63304-964-03</p>
<p><a name="inv-e6a14aff-63cf-4dec-a703-f6b2ebcc9f4e"></a> CEFUROXIME AXETIL FOR ORAL SUSPENSION, USP</p>
<p><a name="inv-98b5b53a-a855-4518-b0e5-c2f29630fb4d"></a> Rx only				50 ml</p>
<div class="Figure">
<a name="ID0EKDBG"></a><img alt="label002" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=135e2dfc-eb47-4d04-a903-a081d36c267e&amp;name=label002.jpg"><p class="MultiMediaCaption">250 mg-5 ml bottle label</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFUROXIME AXETIL FOR ORAL SUSPENSION 		
					</strong><br><span class="contentTableReg">cefuroxime axetil suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-963</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFUROXIME AXETIL</strong> (CEFUROXIME) </td>
<td class="formItem">CEFUROXIME</td>
<td class="formItem">125 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MONOSODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">TUTTI FRUTTI, PEPPERMINT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-963-03</td>
<td class="formItem">50 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63304-963-04</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065323</td>
<td class="formItem">02/08/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFUROXIME AXETIL FOR ORAL SUSPENSION 		
					</strong><br><span class="contentTableReg">cefuroxime axetil suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-964</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFUROXIME AXETIL</strong> (CEFUROXIME) </td>
<td class="formItem">CEFUROXIME</td>
<td class="formItem">250 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MONOSODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">TUTTI FRUTTI, PEPPERMINT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-964-03</td>
<td class="formItem">50 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63304-964-04</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065323</td>
<td class="formItem">02/08/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Ranbaxy Pharmaceuticals Inc
							(937890044)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Ranbaxy Pharmaceuticals Inc (937890044)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">RANBAXY LABORATORIES LIMITED - DEWAS</td>
<td class="formItem"></td>
<td class="formItem">862358806</td>
<td class="formItem">manufacture(63304-963, 63304-964)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>037e5290-f39e-45ef-a05c-51b0ce2c4473</div>
<div>Set id: 135e2dfc-eb47-4d04-a903-a081d36c267e</div>
<div>Version: 1</div>
<div>Effective Time: 20130819</div>
</div>
</div> <div class="DistributorName">Ranbaxy Pharmaceuticals Inc</div></p>
</body></html>
